[go: up one dir, main page]

PE20091091A1 - Compuestos derivados de imidazolona que inhiben el transportador de glicina - Google Patents

Compuestos derivados de imidazolona que inhiben el transportador de glicina

Info

Publication number
PE20091091A1
PE20091091A1 PE2008001575A PE2008001575A PE20091091A1 PE 20091091 A1 PE20091091 A1 PE 20091091A1 PE 2008001575 A PE2008001575 A PE 2008001575A PE 2008001575 A PE2008001575 A PE 2008001575A PE 20091091 A1 PE20091091 A1 PE 20091091A1
Authority
PE
Peru
Prior art keywords
phenyl
methyl
imidazolone
diazaespiro
imidazol
Prior art date
Application number
PE2008001575A
Other languages
English (en)
Inventor
Richard John Blunt
David Gwyn Cooper
Roderick Alan Porter
Paul Adrian Wyman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0717728A external-priority patent/GB0717728D0/en
Priority claimed from GB0802586A external-priority patent/GB0802586D0/en
Priority claimed from GB0813501A external-priority patent/GB0813501D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20091091A1 publication Critical patent/PE20091091A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE IMIDAZOLONA DE FORMULA (I), DONDE X ES -CH2- U O; R1, R2, R3 Y R4 SON H, ALQUILO C1-C4, CN, HALO, ENTRE OTROS; R5 ES H, Cl, F, CF3, ENTRE OTROS; R6 Y R7 SON H, ALQUILO C1-C4, ALCOXI C1-C4, ENTRE OTROS; R8 ES H O METILO; R15 ES H O F; m ES 0, 1 O 2. SON COMPUESTOS PREFERIDOS: 2-{3-[4-(4-METIL-1H-IMIDAZOL-1-IL)FENIL]-2-OXO-1,4-DIAZAESPIRO[4.4]NON-3-EN-1-IL}-N-[3-(TRIFLUOROMETIL)FENIL]ACETAMIDA, 2-{3-[4-(5-METIL-1H-IMIDAZOL-1-IL)FENIL]-2-OXO-1,4-DIAZAESPIRO[4.4]NON-3-EN-1-IL}-N-[3-(TRIFLUOROMETIL)FENIL]ACETAMIDA, 2-{3-[4-(4-METIL-1H-IMIDAZOL-1-IL)FENIL]-2-OXO-1,4-DIAZAESPIRO[4.5]DEC-3-EN-1-IL}-N-[3-(TRIFLUOROMETIL)FENIL]ACETAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL LOS TRANSPORTADORES DE GLICINA GlyT1 Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS NEUROLOGICOS Y NEUROPSIQUIATRICOS TALES COMO PSICOSIS, DEMENCIA O TRANSTORNO DE DEFICIT DE ATENCION
PE2008001575A 2007-09-11 2008-09-09 Compuestos derivados de imidazolona que inhiben el transportador de glicina PE20091091A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0717728A GB0717728D0 (en) 2007-09-11 2007-09-11 Compounds
GB0802586A GB0802586D0 (en) 2008-02-12 2008-02-12 Compounds
GB0813501A GB0813501D0 (en) 2008-07-23 2008-07-23 Pb62624p2

Publications (1)

Publication Number Publication Date
PE20091091A1 true PE20091091A1 (es) 2009-08-28

Family

ID=39877729

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001575A PE20091091A1 (es) 2007-09-11 2008-09-09 Compuestos derivados de imidazolona que inhiben el transportador de glicina

Country Status (9)

Country Link
US (1) US20100317704A1 (es)
EP (1) EP2197852A1 (es)
JP (1) JP2010539128A (es)
AR (1) AR068388A1 (es)
CL (1) CL2008002674A1 (es)
PE (1) PE20091091A1 (es)
TW (1) TW200911234A (es)
UY (1) UY31332A1 (es)
WO (1) WO2009034061A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080221185A1 (en) * 2005-08-02 2008-09-11 Anthony William Dean Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
US20090326027A1 (en) * 2006-03-16 2009-12-31 Steven Coulton N-Phenyl-2-0X0-1,4-Diazaspiro [4.5] Dec-3-EN-1-YL Acetamide Derivatives And Their Use As Glycine Transporter Inhibitors
JP2009530246A (ja) * 2006-03-16 2009-08-27 グラクソ グループ リミテッド グリシントランスポーターを阻害する化合物およびその使用
JP2010517963A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド 神経学的および神経精神病学的障害の治療におけるＧｌｙＴ１トランスポーター阻害薬としての８−オキサ−１，４−ジアザスピロ［４，５］デク−３−エン−１−イルおよび１，４，８−トリアザスピロ［４，５］デク−３−エン−１−イルアセトアミド誘導体
TW200846328A (en) * 2007-02-01 2008-12-01 Glaxo Group Ltd GlyT1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
US20100048656A1 (en) * 2007-02-01 2010-02-25 Nadia Mamoona Ahmad Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders

Also Published As

Publication number Publication date
WO2009034061A1 (en) 2009-03-19
EP2197852A1 (en) 2010-06-23
US20100317704A1 (en) 2010-12-16
JP2010539128A (ja) 2010-12-16
TW200911234A (en) 2009-03-16
AR068388A1 (es) 2009-11-11
UY31332A1 (es) 2009-03-31
CL2008002674A1 (es) 2009-10-16

Similar Documents

Publication Publication Date Title
PE20142294A1 (es) Compuestos de indol e indazol que activan la ampk
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20140236A1 (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS
PE20121182A1 (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
PE20121048A1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
JP2013536188A5 (es)
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20080890A1 (es) DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES
PE20090996A1 (es) Derivados de pirrolopirimidina como inhibidores de cinasa jak3
JP2016505619A5 (es)
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20120911A1 (es) Derivados de prolina como inhibidores de catepsina
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR066155A1 (es) Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia
PE20142282A1 (es) Nuevos derivados de aril-quinolina
PE20140934A1 (es) Derivados de pirazol
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
PE20080143A1 (es) Compuestos 2-oxo-3-fenil-(1,4-diazaespiro[4.5]dec-3-en-1-il)acetamida sustituidos como inhibidores del transportador de glicina
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20151748A1 (es) Inhibidores de bace1
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal